Mankind Pharma Q2FY27 Results: Net profit up 38% YoY, EBITDA margin hits 27.1%
Net profit rose 37.7% YoY to ₹716 crore, beating consensus estimates. EBITDA margin expanded 210 bps to 27.1% due to operating leverage. Domestic revenue (ex-CH) grew 15.9% YoY, led by chronic segment outperformance. Net debt reduced to ₹2,639 crore, improving Net Debt/EBITDA ratio to 0.6x. Board approved merger of two wholly owned subsidiaries for structural consolidation.